APO Research
Talk to an analyst

APO RESEARCH · REPORT

Intravenous Immunoglobulin(IVIg) Therapy

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Intravenous Immunoglobulin(IVIg) Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025196 pages

Choose your research edition.

Industry ResearchIntravenous Immunoglobulin(IVIg) Therapy Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Intravenous Immunoglobulin(IVIg) Therapy Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Intravenous Immunoglobulin(IVIg) Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intravenous Immunoglobulin(IVIg) Therapy Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Intravenous Immunoglobulin(IVIg) Therapy Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Intravenous Immunoglobulin(IVIg) Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Intravenous Immunoglobulin(IVIg) Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Intravenous Immunoglobulin(IVIg) Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Intravenous Immunoglobulin(IVIg) Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Intravenous Immunoglobulin(IVIg) Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Intravenous Immunoglobulin(IVIg) Therapy include TEIJIN LIMITED, Baxter, Biotest, Boya-Bio, CNBG, CSL Plasma, Grifols, Kamada and Kedrion, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Intravenous Immunoglobulin(IVIg) Therapy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Intravenous Immunoglobulin(IVIg) Therapy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Intravenous Immunoglobulin(IVIg) Therapy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Intravenous Immunoglobulin(IVIg) Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.

Intravenous Immunoglobulin(IVIg) Therapy Segment by Company

TEIJIN LIMITED

Baxter

Biotest

Boya-Bio

CNBG

CSL Plasma

Grifols

Kamada

Kedrion

LFB Group

Nanyue Biopharming

Octapharma

Sinopharm

Beijing Tiantan Biological Products

Guangdong Shuagnlin Bio-pharmacy

Hualan Bio

Shanghai RAAS

Weiguang Biological

Taibang Biologic Group

Takeda

Intravenous Immunoglobulin(IVIg) Therapy Segment by Type

5g/100ml

2.5g/50ml

1g/20ml

10g/200ml

1.25g/25ml

Others

Intravenous Immunoglobulin(IVIg) Therapy Segment by Application

Autoimmune Disease

Immunodeficiency

Acute Infection

Others

Intravenous Immunoglobulin(IVIg) Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous Immunoglobulin(IVIg) Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intravenous Immunoglobulin(IVIg) Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous Immunoglobulin(IVIg) Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Intravenous Immunoglobulin(IVIg) Therapy market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Intravenous Immunoglobulin(IVIg) Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Intravenous Immunoglobulin(IVIg) Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Intravenous Immunoglobulin(IVIg) Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Intravenous Immunoglobulin(IVIg) Therapy Industry Trends Table 2. Intravenous Immunoglobulin(IVIg) Therapy Industry Drivers Table 3. Intravenous Immunoglobulin(IVIg) Therapy Industry Opportunities and Challenges Table 4. Intravenous Immunoglobulin(IVIg) Therapy Industry Restraints Table 5. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Manufacturers Table 9. Global Intravenous Immunoglobulin(IVIg) Therapy Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Intravenous Immunoglobulin(IVIg) Therapy Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Intravenous Immunoglobulin(IVIg) Therapy Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Intravenous Immunoglobulin(IVIg) Therapy Manufacturers, Product Type & Application Table 13. Global Intravenous Immunoglobulin(IVIg) Therapy Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Intravenous Immunoglobulin(IVIg) Therapy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 5g/100ml Table 17. Major Manufacturers of 2.5g/50ml Table 18. Major Manufacturers of 1g/20ml Table 19. Major Manufacturers of 10g/200ml Table 20. Major Manufacturers of 1.25g/25ml Table 21. Major Manufacturers of Others Table 22. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2021-2026) & (K Units) Table 24. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2027-2032) & (K Units) Table 25. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Type (2021-2026) Table 26. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Type (2027-2032) Table 27. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2021-2026) & (K Units) Table 29. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2027-2032) & (K Units) Table 30. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Type (2021-2026) Table 31. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Autoimmune Disease Table 33. Major Manufacturers of Immunodeficiency Table 34. Major Manufacturers of Acute Infection Table 35. Major Manufacturers of Others Table 36. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2021-2026) & (K Units) Table 38. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2027-2032) & (K Units) Table 39. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Application (2021-2026) Table 40. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Application (2027-2032) Table 41. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2021-2026) & (K Units) Table 43. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2027-2032) & (K Units) Table 44. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Application (2021-2026) Table 45. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Application (2027-2032) Table 46. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2021-2026) & (K Units) Table 48. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Region (2021-2026) Table 49. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Intravenous Immunoglobulin(IVIg) Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026) & (K Units) Table 53. North America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032) & (K Units) Table 54. Europe Intravenous Immunoglobulin(IVIg) Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026) & (K Units) Table 56. Europe Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032) & (K Units) Table 63. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Region (2021-2026) Table 67. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Region (2027-2032) Table 68. TEIJIN LIMITED Company Information Table 69. TEIJIN LIMITED Business Overview Table 70. TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 72. TEIJIN LIMITED Recent Development Table 73. Baxter Company Information Table 74. Baxter Business Overview Table 75. Baxter Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Baxter Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 77. Baxter Recent Development Table 78. Biotest Company Information Table 79. Biotest Business Overview Table 80. Biotest Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Biotest Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 82. Biotest Recent Development Table 83. Boya-Bio Company Information Table 84. Boya-Bio Business Overview Table 85. Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 87. Boya-Bio Recent Development Table 88. CNBG Company Information Table 89. CNBG Business Overview Table 90. CNBG Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. CNBG Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 92. CNBG Recent Development Table 93. CSL Plasma Company Information Table 94. CSL Plasma Business Overview Table 95. CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 97. CSL Plasma Recent Development Table 98. Grifols Company Information Table 99. Grifols Business Overview Table 100. Grifols Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Grifols Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 102. Grifols Recent Development Table 103. Kamada Company Information Table 104. Kamada Business Overview Table 105. Kamada Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Kamada Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 107. Kamada Recent Development Table 108. Kedrion Company Information Table 109. Kedrion Business Overview Table 110. Kedrion Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Kedrion Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 112. Kedrion Recent Development Table 113. LFB Group Company Information Table 114. LFB Group Business Overview Table 115. LFB Group Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. LFB Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 117. LFB Group Recent Development Table 118. Nanyue Biopharming Company Information Table 119. Nanyue Biopharming Business Overview Table 120. Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 122. Nanyue Biopharming Recent Development Table 123. Octapharma Company Information Table 124. Octapharma Business Overview Table 125. Octapharma Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Octapharma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 127. Octapharma Recent Development Table 128. Sinopharm Company Information Table 129. Sinopharm Business Overview Table 130. Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 132. Sinopharm Recent Development Table 133. Beijing Tiantan Biological Products Company Information Table 134. Beijing Tiantan Biological Products Business Overview Table 135. Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 137. Beijing Tiantan Biological Products Recent Development Table 138. Guangdong Shuagnlin Bio-pharmacy Company Information Table 139. Guangdong Shuagnlin Bio-pharmacy Business Overview Table 140. Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 142. Guangdong Shuagnlin Bio-pharmacy Recent Development Table 143. Hualan Bio Company Information Table 144. Hualan Bio Business Overview Table 145. Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 147. Hualan Bio Recent Development Table 148. Shanghai RAAS Company Information Table 149. Shanghai RAAS Business Overview Table 150. Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 152. Shanghai RAAS Recent Development Table 153. Weiguang Biological Company Information Table 154. Weiguang Biological Business Overview Table 155. Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 157. Weiguang Biological Recent Development Table 158. Taibang Biologic Group Company Information Table 159. Taibang Biologic Group Business Overview Table 160. Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 162. Taibang Biologic Group Recent Development Table 163. Takeda Company Information Table 164. Takeda Business Overview Table 165. Takeda Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Takeda Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 167. Takeda Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. Intravenous Immunoglobulin(IVIg) Therapy Distributors List Table 171. Intravenous Immunoglobulin(IVIg) Therapy Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Intravenous Immunoglobulin(IVIg) Therapy Product Image Figure 2. Global Intravenous Immunoglobulin(IVIg) Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Intravenous Immunoglobulin(IVIg) Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Intravenous Immunoglobulin(IVIg) Therapy Sales (2021-2032) & (K Units) Figure 5. Global Intravenous Immunoglobulin(IVIg) Therapy Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Intravenous Immunoglobulin(IVIg) Therapy Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 5g/100ml Image Figure 9. 2.5g/50ml Image Figure 10. 1g/20ml Image Figure 11. 10g/200ml Image Figure 12. 1.25g/25ml Image Figure 13. Others Image Figure 14. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Type (2021-2032) Figure 17. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Type (2021-2032) Figure 20. Autoimmune Disease Image Figure 21. Immunodeficiency Image Figure 22. Acute Infection Image Figure 23. Others Image Figure 24. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Application (2021-2032) Figure 27. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Application (2021-2032) Figure 30. North America Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2021-2032) Figure 32. U.S. Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2021-2032) Figure 37. Germany Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2021-2032) Figure 44. China Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2021-2032) Figure 52. Brazil Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Intravenous Immunoglobulin(IVIg) Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Intravenous Immunoglobulin(IVIg) Therapy Revenue (2021-2032) & (US$ Million) Figure 63. North America Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue (2021-2032) & (US$ Million) Figure 65. Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Intravenous Immunoglobulin(IVIg) Therapy Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Intravenous Immunoglobulin(IVIg) Therapy Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • 5g/100ml
  • 2.5g/50ml
  • 1g/20ml
  • 10g/200ml
  • 1.25g/25ml
  • Others
Applications
  • Autoimmune Disease
  • Immunodeficiency
  • Acute Infection
  • Others
Companies covered
  • TEIJIN LIMITED
  • Baxter
  • Biotest
  • Boya-Bio
  • CNBG
  • CSL Plasma
  • Grifols
  • Kamada
  • Kedrion
  • LFB Group
  • Nanyue Biopharming
  • Octapharma
  • Sinopharm
  • Beijing Tiantan Biological Products
  • Guangdong Shuagnlin Bio-pharmacy
  • Hualan Bio
  • Shanghai RAAS
  • Weiguang Biological
  • Taibang Biologic Group
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Intravenous Immunoglobulin(IVIg) Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Intravenous Immunoglobulin(IVIg) Therapy Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Intravenous Immunoglobulin(IVIg) Therapy Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Intravenous Immunoglobulin(IVIg) Therapy Market Dynamics
  1. 2.1 Intravenous Immunoglobulin(IVIg) Therapy Industry Trends
  2. 2.2 Intravenous Immunoglobulin(IVIg) Therapy Industry Drivers
  3. 2.3 Intravenous Immunoglobulin(IVIg) Therapy Industry Opportunities and Challenges
  4. 2.4 Intravenous Immunoglobulin(IVIg) Therapy Industry Restraints
3 Intravenous Immunoglobulin(IVIg) Therapy Market by Manufacturers
  1. 3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Manufacturers (2021-2026)
  3. 3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Intravenous Immunoglobulin(IVIg) Therapy Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Intravenous Immunoglobulin(IVIg) Therapy Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Intravenous Immunoglobulin(IVIg) Therapy Manufacturers, Product Type & Application
  7. 3.7 Global Intravenous Immunoglobulin(IVIg) Therapy Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Intravenous Immunoglobulin(IVIg) Therapy Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Intravenous Immunoglobulin(IVIg) Therapy Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Intravenous Immunoglobulin(IVIg) Therapy Tier 1, Tier 2, and Tier 3
4 Intravenous Immunoglobulin(IVIg) Therapy Market by Type
  1. 4.1 Intravenous Immunoglobulin(IVIg) Therapy Type Introduction
  2. 4.1.1 5g/100ml
  3. 4.1.2 2.5g/50ml
  4. 4.1.3 1g/20ml
  5. 4.1.4 10g/200ml
  6. 4.1.5 1.25g/25ml
  7. 4.1.6 Others
  8. 4.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type
  9. 4.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2021-2032)
  11. 4.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Type (2021-2032)
  12. 4.3 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type
  13. 4.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2021-2032)
  15. 4.3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Type (2021-2032)
5 Intravenous Immunoglobulin(IVIg) Therapy Market by Application
  1. 5.1 Intravenous Immunoglobulin(IVIg) Therapy Application Introduction
  2. 5.1.1 Autoimmune Disease
  3. 5.1.2 Immunodeficiency
  4. 5.1.3 Acute Infection
  5. 5.1.4 Others
  6. 5.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application
  7. 5.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2021-2032)
  9. 5.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Application (2021-2032)
  10. 5.3 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application
  11. 5.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2021-2032)
  13. 5.3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Application (2021-2032)
6 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region
  1. 6.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2021-2032)
  3. 6.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2021-2026)
  4. 6.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Intravenous Immunoglobulin(IVIg) Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Intravenous Immunoglobulin(IVIg) Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region
  1. 7.1 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region
  2. 7.1.1 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region (2021-2026)
  4. 7.1.3 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region (2027-2032)
  5. 7.1.4 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Intravenous Immunoglobulin(IVIg) Therapy Revenue (2021-2032)
  8. 7.2.2 North America Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue (2021-2032)
  11. 7.3.2 Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 TEIJIN LIMITED
  2. 8.1.1 TEIJIN LIMITED Company Information
  3. 8.1.2 TEIJIN LIMITED Business Overview
  4. 8.1.3 TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  6. 8.1.5 TEIJIN LIMITED Recent Developments
  7. 8.2 Baxter
  8. 8.2.1 Baxter Company Information
  9. 8.2.2 Baxter Business Overview
  10. 8.2.3 Baxter Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Baxter Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  12. 8.2.5 Baxter Recent Developments
  13. 8.3 Biotest
  14. 8.3.1 Biotest Company Information
  15. 8.3.2 Biotest Business Overview
  16. 8.3.3 Biotest Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biotest Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  18. 8.3.5 Biotest Recent Developments
  19. 8.4 Boya-Bio
  20. 8.4.1 Boya-Bio Company Information
  21. 8.4.2 Boya-Bio Business Overview
  22. 8.4.3 Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  24. 8.4.5 Boya-Bio Recent Developments
  25. 8.5 CNBG
  26. 8.5.1 CNBG Company Information
  27. 8.5.2 CNBG Business Overview
  28. 8.5.3 CNBG Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CNBG Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  30. 8.5.5 CNBG Recent Developments
  31. 8.6 CSL Plasma
  32. 8.6.1 CSL Plasma Company Information
  33. 8.6.2 CSL Plasma Business Overview
  34. 8.6.3 CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  36. 8.6.5 CSL Plasma Recent Developments
  37. 8.7 Grifols
  38. 8.7.1 Grifols Company Information
  39. 8.7.2 Grifols Business Overview
  40. 8.7.3 Grifols Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Grifols Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  42. 8.7.5 Grifols Recent Developments
  43. 8.8 Kamada
  44. 8.8.1 Kamada Company Information
  45. 8.8.2 Kamada Business Overview
  46. 8.8.3 Kamada Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kamada Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  48. 8.8.5 Kamada Recent Developments
  49. 8.9 Kedrion
  50. 8.9.1 Kedrion Company Information
  51. 8.9.2 Kedrion Business Overview
  52. 8.9.3 Kedrion Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Kedrion Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  54. 8.9.5 Kedrion Recent Developments
  55. 8.10 LFB Group
  56. 8.10.1 LFB Group Company Information
  57. 8.10.2 LFB Group Business Overview
  58. 8.10.3 LFB Group Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 LFB Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  60. 8.10.5 LFB Group Recent Developments
  61. 8.11 Nanyue Biopharming
  62. 8.11.1 Nanyue Biopharming Company Information
  63. 8.11.2 Nanyue Biopharming Business Overview
  64. 8.11.3 Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  66. 8.11.5 Nanyue Biopharming Recent Developments
  67. 8.12 Octapharma
  68. 8.12.1 Octapharma Company Information
  69. 8.12.2 Octapharma Business Overview
  70. 8.12.3 Octapharma Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Octapharma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  72. 8.12.5 Octapharma Recent Developments
  73. 8.13 Sinopharm
  74. 8.13.1 Sinopharm Company Information
  75. 8.13.2 Sinopharm Business Overview
  76. 8.13.3 Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  78. 8.13.5 Sinopharm Recent Developments
  79. 8.14 Beijing Tiantan Biological Products
  80. 8.14.1 Beijing Tiantan Biological Products Company Information
  81. 8.14.2 Beijing Tiantan Biological Products Business Overview
  82. 8.14.3 Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  84. 8.14.5 Beijing Tiantan Biological Products Recent Developments
  85. 8.15 Guangdong Shuagnlin Bio-pharmacy
  86. 8.15.1 Guangdong Shuagnlin Bio-pharmacy Company Information
  87. 8.15.2 Guangdong Shuagnlin Bio-pharmacy Business Overview
  88. 8.15.3 Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  90. 8.15.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
  91. 8.16 Hualan Bio
  92. 8.16.1 Hualan Bio Company Information
  93. 8.16.2 Hualan Bio Business Overview
  94. 8.16.3 Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  96. 8.16.5 Hualan Bio Recent Developments
  97. 8.17 Shanghai RAAS
  98. 8.17.1 Shanghai RAAS Company Information
  99. 8.17.2 Shanghai RAAS Business Overview
  100. 8.17.3 Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  102. 8.17.5 Shanghai RAAS Recent Developments
  103. 8.18 Weiguang Biological
  104. 8.18.1 Weiguang Biological Company Information
  105. 8.18.2 Weiguang Biological Business Overview
  106. 8.18.3 Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  108. 8.18.5 Weiguang Biological Recent Developments
  109. 8.19 Taibang Biologic Group
  110. 8.19.1 Taibang Biologic Group Company Information
  111. 8.19.2 Taibang Biologic Group Business Overview
  112. 8.19.3 Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  114. 8.19.5 Taibang Biologic Group Recent Developments
  115. 8.20 Takeda
  116. 8.20.1 Takeda Company Information
  117. 8.20.2 Takeda Business Overview
  118. 8.20.3 Takeda Intravenous Immunoglobulin(IVIg) Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Takeda Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  120. 8.20.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Intravenous Immunoglobulin(IVIg) Therapy Value Chain Analysis
  2. 9.1.1 Intravenous Immunoglobulin(IVIg) Therapy Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Intravenous Immunoglobulin(IVIg) Therapy Production Mode & Process
  6. 9.2 Intravenous Immunoglobulin(IVIg) Therapy Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Intravenous Immunoglobulin(IVIg) Therapy Distributors
  9. 9.2.3 Intravenous Immunoglobulin(IVIg) Therapy Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst